Big Pharma Demands Trump Punish Australia for Affordable Medicines
The Pharmaceutical Benefits Scheme (PBS), while a “world-class” program providing affordable medications to Australians, faces criticism from US pharmaceutical companies for its processes. These companies allege the PBS employs biased assessments, imposes unreasonable delays in approving new medicines, and creates unnecessary administrative hurdles. This criticism carries significant cost implications for the Australian government and raises the potential for US trade retaliation, though experts offer differing perspectives on the likelihood of such action. Despite assurances from both major Australian political parties to protect the PBS, the precedent of US tariffs on other Australian goods demonstrates the vulnerability of the system to external pressure.
John Q. Hosedrinker